Alaunos Therapeutics, Inc. (TCRT) - 10-Q Summary for Q1 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company that has strategically reprioritized its operations to focus on an internally developed Obesity and Metabolic Disorders Program (lead candidate ALN1003). The Company is classified as a Non-Accelerated Filer and a Smaller Reporting Company. As of May 15, 2026, there were approximately 2,442,146 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $2,000 |
| Net Loss | $(1,006,000) | $(1,073,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.59) | $(0.67) |
| Cash and Cash Equivalents (End of Period) | $354,000 | $319,000 |
| Operating Cash Flow | $(1,031,000) | $(772,000) |
| Total Assets | $1,883,000 | $2,966,000 |
| Total Liabilities | $595,000 | $813,000 |
| Stockholders' Equity | $1,288,000 | $2,153,000 |
| Accumulated Deficit | $(925.6 million) | $(921.5 million) |
Note: All financial figures are in thousands unless otherwise noted.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero from $2,000 in the prior year quarter, as no royalty or collaboration revenue was recognized under the Solasia agreement during Q1 2026.
- Operating Expenses: Total operating expenses decreased by approximately 7.5% to $1.012 million.
- R&D Expenses: Increased by $80,000 (23%) to $427,000, driven by stock-based compensation, salaries, and consulting fees related to the obesity program.
- G&A Expenses: Decreased by $162,000 (22%) to $585,000, attributed to reduced salaries, insurance, filing fees, and travel costs due to downsized operations.
- Liquidity: Cash and cash equivalents increased slightly to $354,000 from $319,000 year-over-year, but decreased significantly from $1.385 million at the end of 2025 due to a cash burn rate of approximately $340,000 per month.
- Equity: Stockholders' equity declined to $1.288 million, falling below the Nasdaq minimum requirement of $2.5 million.
Outlook, Risks, and Management Commentary
Going Concern and Liquidity: Management has raised substantial doubt about the Company's ability to continue as a going concern. With a cash balance of $0.35 million and a monthly burn rate of ~$0.34 million, the Company expects to fund operations only into the second quarter of 2026. Substantial additional capital is required to advance the ALN1003 program or continue operations.
Nasdaq Compliance: On April 9, 2026, the Company received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement ($2.5 million). The Company has 45 days to submit a compliance plan. Failure to regain compliance could result in delisting.
Program Progress (ALN1003):
- Recent non-GLP studies in diet-induced obesity (DIO) mouse models demonstrated proof-of-concept, showing dose-dependent body weight loss, improved body composition (fat loss with lean mass preservation), and favorable metabolic biomarkers.
- Studies indicated reductions in liver weight and improvements in liver function biomarkers.
- The Company plans to conduct additional preclinical studies, formulation optimization, and manufacturing scale-up to support IND-enabling activities, contingent on securing funding.
Risks and Contingencies:
- Capital Needs: Failure to raise additional capital could force the Company to curtail operations, pursue dissolution, or liquidate.
- Internal Controls: The Company identified a material weakness in its internal control environment, which may result in material misstatements.
- Legal: A settlement with MD Anderson requires payments of $285,000 in installments through May 30, 2026.
Investor Verification Checklist
- Cash Runway: Verify the exact date cash resources are projected to be exhausted (currently estimated as Q2 2026) and the status of any fundraising efforts.
- Nasdaq Compliance Plan: Confirm if a compliance plan has been submitted to Nasdaq and the likelihood of regaining listing status to avoid delisting.
- Capital Structure: Review the terms of the Series A-1 and A-2 Preferred Stock, including the 10% cumulative dividends that accrue and increase the liquidation preference.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal controls over financial reporting.
- MD Anderson Settlement: Confirm the status of the remaining payments under the $285,000 settlement agreement.